AR122344A1 - USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS - Google Patents

USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS

Info

Publication number
AR122344A1
AR122344A1 ARP200103359A ARP200103359A AR122344A1 AR 122344 A1 AR122344 A1 AR 122344A1 AR P200103359 A ARP200103359 A AR P200103359A AR P200103359 A ARP200103359 A AR P200103359A AR 122344 A1 AR122344 A1 AR 122344A1
Authority
AR
Argentina
Prior art keywords
reboxetine
nervous system
system disorders
treat nervous
esreboxetine
Prior art date
Application number
ARP200103359A
Other languages
Spanish (es)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of AR122344A1 publication Critical patent/AR122344A1/en

Links

Abstract

En el presente documento se describen métodos para tratar la narcolepsia con cataplejía, que comprenden administrar reboxetina (incluida esreboxetina) a un ser humano que lo necesite. La reboxetina (incluida la esreboxetina) también se puede utilizar en la fabricación de un medicamento para el tratamiento de la narcolepsia con cataplejía. También se describen en el presente documento kits que comprenden una composición farmacéutica que comprende reboxetina (incluida esreboxetina) e instrucciones para usar la composición farmacéutica para tratar la narcolepsia con cataplejía en un ser humano.Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human in need thereof. Reboxetine (including esreboxetine) can also be used in the manufacture of a drug for the treatment of narcolepsy with cataplexy. Also described herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions for using the pharmaceutical composition to treat narcolepsy with cataplexy in a human.

ARP200103359A 2019-12-03 2020-12-02 USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS AR122344A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962943077P 2019-12-03 2019-12-03

Publications (1)

Publication Number Publication Date
AR122344A1 true AR122344A1 (en) 2022-09-07

Family

ID=83444526

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103359A AR122344A1 (en) 2019-12-03 2020-12-02 USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS

Country Status (1)

Country Link
AR (1) AR122344A1 (en)

Similar Documents

Publication Publication Date Title
CL2021000924A1 (en) Use of reboxetine for the treatment of narcolepsy
GT201700246A (en) METHODS AND KITS TO TREAT DEPRESSION
CL2017002996A1 (en) Tetra-substituted alkene compounds and their use
CL2022001743A1 (en) Gamma-Hydroxybutyrate (GHB) Dosage
BR112016027773A2 (en) cell penetrating peptide, polynucleotide, recombinant botulinum toxin penetrating cell protein, recombinant expression vector, bacterium, pharmaceutical composition, cosmetic composition and method for producing a recombinant botulinum toxin cell penetrating protein
MX2020009773A (en) Combination therapy.
BR112015026122A8 (en) polyethylene glycol-yl-10 agent (peg-il-10), its use, pharmaceutical composition, sterile container and kit
MX2019003134A (en) Combination therapy.
BR112017006113A8 (en) Auristatin uses, pharmaceutical compositions, dosage forms for cancer treatment and kits.
BR112023005160A2 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER
BR112018076639A2 (en) combination chemotherapies
CO2021015793A2 (en) Methods of treating or preventing asthma by administering an il-33 antagonist
CL2021001976A1 (en) Treatment of skin lesions and pruritus in patients with nodular prurigo
BR112022010702A2 (en) MACROCYCLES FOR USE IN THE TREATMENT OF DISEASES
CO2022014499A2 (en) nlrp3 modulators
CO2022008001A2 (en) Methods for treating depressive disorders
CL2020000270A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor.
EA202091112A1 (en) SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION
JOP20200031A1 (en) Methods of treatment of osteoarthritis with transdermal cannabidiol gel
CO2023014650A2 (en) Dosage and administration of recombinant l-asparaginase
BR112019004540A2 (en) method for treating dementia in a patient, pharmaceutical composition, method for treating dementia in a patient, method for reducing the likelihood of developing dementia in a patient, composition for use in treating dementia in a patient, composition and composition for use in reducing dementia likelihood of developing dementia in a patient undergoing long therapy with a non-steroidal anti-inflammatory drug or aspirin
AR122344A1 (en) USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS
PE20230181A1 (en) USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS
CL2022001476A1 (en) Use of reboxetine to treat disorders of the nervous system
DOP2022000095A (en) DOSAGE REGIMES FOR USE IN THE TREATMENT OF MYELOFIBROSIS AND MPN-RELATED DISORDERS WITH NAVITOCLAX